Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
European Institute of Oncology |
---|---|
Information provided by: | European Institute of Oncology |
ClinicalTrials.gov Identifier: | NCT00292526 |
In cancer patients, the increase of troponin I soon after chemotherapy is a strong predictor of left ventricular dysfunction and poor cardiologic outcome. This information provides a rationale for the development of prophylactic strategies directed against chemotherapy-induced cardiotoxicity (CTIC). Activation of the renin-angiotensin system has been proved to be involved in the development and progression of cardiac dysfunction in several clinical settings, and has been suggested to have a role in the occurrence of CTIC. We investigated the role of treatment with ACE-inhibitors in the prevention of CTIC in high-risk cancer patients.
Condition | Intervention | Phase |
---|---|---|
Chemotherapy-Induced Cardiotoxicity Revealed by TnI Increase. |
Drug: oral enalapril |
Phase IV |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Single Blind, Placebo Control, Parallel Assignment, Efficacy Study |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
Italy | |
European Institute of Oncology | |
Milan, Italy, 20141 |
Study Director: | Carlo M Cipolla, MD | European Institute of Oncology |
Principal Investigator: | Daniela Cardinale, MD | European Institute of Oncology |
Study ID Numbers: | IEO S67/500 |
Study First Received: | February 15, 2006 |
Last Updated: | February 15, 2006 |
ClinicalTrials.gov Identifier: | NCT00292526 History of Changes |
Health Authority: | Italy: Ministry of Health |
Chemotherapy-induced cardiotoxicity Troponin Heart failure |
Enalapril Heart Failure Enalaprilat |